Risk factor
Resilient to price shocks
Profitability factor
Favourable analyst view
About
Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBITD
Target Price
The average target price of PPLPHARMA.NS is 243 and suggests 47% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to
Buy
Sell